uniQure plans to start a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance…

Prima Biomed has pushed the accelerator on its in-house drug development program, pressing ahead with two trials of its immuno-oncology drug IMP321 in breast…

Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a context with J&J's big-selling Prezista.

VC Versant has pumped $20 million on its own into its newly launched preclinical liver disease upstart Jecure, with its founders coming out from a former…

Ardelyx has hit its primary endpoint for its key asset tenapanor in a phase 3 hyperphosphatemia test—a much needed positive after years of trial setbacks.

Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail.

It's been a torrid few days for antiviral drug developer Aviragen as a second phase 2 trial ended in failure, all but decapitating its R&D pipeline.

Incyte will work alone on developing and selling the GITR and OX40 antibody programs that it has been working on with Agenus as the partners retool their…

Almac Discovery and the Royal College of Surgeons in Ireland have teamed up to research the effect of ALM201 on cancer stem cells.

Gilead has posted upbeat phase 2 data on its next-generation integrase inhibitor bictegravir in HIV patients.

R&D